august
commemor
frankfurt
main
germani
anniversari
death
paul
ehrlich
founder
first
institut
pharmacolog
experiment
therapeut
frankfurt
univers
first
director
chemotherapeut
research
institut
home
institut
tumor
biolog
experiment
therapi
figur
ehrlich
first
scientist
stain
blood
cell
also
identifi
inherit
immun
propound
side
chain
theori
antibodi
action
receiv
nobel
prize
medicin
togeth
eli
ehrlich
also
discov
salvarsan
figur
arsen
compound
treatment
syphili
show
methylen
blue
could
use
treatment
malaria
suggest
chemic
compound
could
use
magic
bullet
zauberkugel
select
kill
organ
idea
partial
realiz
explos
develop
recent
year
monoclon
antibodi
pharmacologist
concept
magic
bullet
remain
unattain
dream
much
like
abl
hit
target
accuraci
speed
chemic
bullet
therapeut
target
irrit
habit
move
around
scientif
research
essenti
ration
occup
phenomena
frequent
reduc
simplest
system
studi
look
lead
biomed
journal
attract
color
diagram
simplifi
interact
process
among
first
catch
eye
easili
forget
live
organ
continu
state
dynam
interact
adapt
biochem
synthes
burst
dissip
cell
grow
die
remain
almost
continu
move
molecul
cell
surfac
cytoplasm
visual
simultan
would
probabl
look
like
video
time
squar
piccadilli
circu
place
de
letoil
rush
hour
mesmer
mobil
taken
much
account
consid
effect
pharmacolog
agent
particularli
dynam
homeostat
balanc
maintain
treatment
mean
move
target
molecul
aim
drug
may
move
locat
organ
organ
transport
within
bodi
deliveri
drug
crucial
import
molecul
may
present
higher
express
rate
individu
result
diseas
other
may
absent
consequ
genet
differ
singl
nucleotid
polymorph
test
drug
effect
corollari
target
may
move
treat
organ
modifi
drug
instanc
degrad
drug
mean
bullet
lose
momentum
bare
reach
target
addit
transport
protein
eg
express
carri
drug
back
outsid
target
cell
drug
effect
observ
may
unrel
target
aim
unbeknown
medic
hunter
shot
slice
total
unexpect
target
hit
lead
effect
chang
mark
effect
precis
pharmaceut
bullet
sinc
reproduc
treatment
consider
altern
target
molecul
transform
oncolog
sens
may
occur
differ
isoform
conform
chang
differenti
express
respons
cell
stimuli
pathophysiolog
process
modifi
time
cultur
time
day
result
age
chang
natur
target
modifi
accuraci
drug
appear
true
assess
efficaci
one
studi
popul
longer
true
differ
condit
posit
effect
contribut
part
grow
interest
repurpos
known
drug
novel
therapeut
outwork
move
target
becom
immedi
obviou
pharmacolog
bullet
overshoot
target
hit
someth
els
end
undesir
last
year
anoth
aspect
sort
collater
damag
reveal
fact
mani
publish
highli
reput
poorli
target
seem
place
everi
lab
may
due
among
thing
poor
experiment
design
method
inadequ
sampl
fals
use
statist
lack
suitabl
control
simpli
much
hast
get
data
publish
case
target
incorrect
becom
wobbl
fall
complet
number
measur
counter
superfici
scienc
taken
variou
organ
includ
nation
institut
health
unit
state
uk
nation
centr
replac
refin
reduct
anim
research
european
colleg
neuropsychopharmacolog
well
sever
lead
hope
enhanc
robust
reproduc
vari
condit
differ
gene
express
organ
cell
studi
time
day
dose
differ
metabol
fate
chemic
agent
though
also
contribut
contradictori
find
draw
extent
person
experi
particularli
field
inflamm
auto
immun
review
reason
mobil
drug
target
interact
ligand
figur
result
pharmacolog
plastic
take
consider
inher
chemic
dynam
target
molecul
address
neuron
plastic
cn
inher
highli
plastic
new
neuron
connect
pathway
gener
lost
respons
emot
experi
environment
stress
learn
diseas
trauma
condit
subject
extens
suggest
howev
way
drug
target
made
stand
still
least
becom
easier
hit
mani
approach
alreadi
known
emphas
import
take
vari
condit
account
holist
manner
develop
drug
explain
effect
attempt
tackl
biolog
traffic
mele
chronic
diseas
present
gene
mutat
one
wide
appreci
sourc
variabl
respons
drug
occur
rel
infrequ
effect
deoxyribonucl
acid
dna
repair
mechan
cell
compet
immun
surveil
environment
select
pressur
mutat
rate
increas
immun
defens
mean
epitop
drift
occur
togeth
loss
antigen
host
immun
attack
virus
probabl
champion
order
avoid
destruct
vaccin
drug
global
concern
awaken
recent
epidem
influenza
sever
acut
respiratori
syndrom
ebola
zika
virus
need
effect
antivir
becom
urgent
promis
way
forward
caprici
virus
human
immunodefici
viru
hiv
appear
hit
viru
differ
site
multival
approach
also
prove
effect
drug
therapi
hiv
infect
combin
drug
includ
nucleotid
revers
transcriptas
inhibitor
proteas
inhibitor
viral
entri
inhibitor
introduct
highli
activ
therapi
compos
least
three
differ
drug
effect
reduc
mutat
rate
enabl
mani
chronic
patient
live
rel
normal
combin
therapi
direct
specif
viral
target
also
extens
investig
therapi
viral
infect
includ
hepat
b
viru
hbv
infect
combin
recent
howev
inclus
hepat
c
protein
inhibitor
sovosbuvir
antivir
drug
combin
dramat
enhanc
success
rate
treatment
genotyp
hepat
c
indic
valu
aim
specif
crucial
target
specif
use
therapeut
armament
indiscrimin
like
shotgun
therapeut
outcom
potenti
wors
diseas
origin
target
case
indiscrimin
use
ddt
highlight
mileston
book
silent
spring
rachel
carson
result
extens
environment
damag
spawn
ecolog
movement
mani
way
face
similar
situat
indiscrimin
use
antibiot
particularli
nutrit
livestock
viral
infect
actual
promot
bacteri
resist
mechan
drug
efflux
warn
global
increas
bacteri
resist
antibiot
consequ
loss
treatment
option
mani
infect
common
govern
industri
start
joint
effort
combat
situat
highlight
import
take
approach
also
increas
specif
develop
effect
rapid
diagnost
procedur
identifi
potenti
etiolog
receptor
gpcr
cell
membran
repres
major
famili
molecular
target
varieti
differ
drug
recent
shown
basi
analysi
uk
nation
health
servic
drug
prescript
sale
data
individu
averag
individu
carri
least
one
allel
mutat
activ
site
gpcr
drug
gpcr
incid
missens
chang
much
higher
thu
individu
carri
least
one
missens
mutat
allel
activ
site
cannabinoid
receptor
glucagon
like
peptid
receptor
respect
two
gpcr
target
common
antiemet
nabilon
sever
antidiabet
drug
exenatid
respect
class
drug
incid
mutat
suggest
extens
propens
popul
genet
induc
differenti
even
absent
respons
drug
act
gpcr
author
actual
test
experiment
variant
receptor
confirm
differ
respons
action
variant
receptor
compar
receptor
obtain
full
agonist
morphin
partial
agonist
buprenorphin
antagonist
naloxon
endogen
agonist
togeth
infecti
diseas
lifestyl
disord
cancer
major
global
indic
drug
develop
plastic
chang
tumor
long
stymi
specif
therapeut
target
strategi
chang
includ
uncoupl
homeostat
regul
growth
tumor
cell
resist
drug
therapi
instanc
overexpress
efflux
transport
aggress
invas
surround
tissu
although
new
approach
kinas
inhibit
immun
checkpoint
therapi
begin
impact
use
cytotox
drug
remain
mainstay
oncolog
treatment
drug
affect
wide
spectrum
cellular
growth
process
advers
effect
cytotox
drug
particularli
gastrointestin
system
pronounc
sinist
genet
effect
aris
instanc
treatment
mice
chemotherapeut
agent
cyclophosphamid
mitomycin
c
procarbazin
caus
appar
instabl
signific
elev
simpl
tandem
repeat
mutat
frequenc
sperm
bone
marrow
thu
intergener
effect
anticanc
therapi
may
potenti
place
children
treat
parent
risk
suggest
warn
potenti
effect
offspr
given
patient
childbear
age
treat
chemotherapi
infecti
diseas
collater
damag
caus
nonspecif
cytostat
therapi
could
well
health
threat
futur
gener
highli
specif
could
well
better
option
fact
recent
research
suggest
varieti
differ
tumor
type
exhibit
recurr
regulatori
structur
consist
function
master
regul
protein
dysregul
posttransl
multipl
target
network
master
regul
protein
potenti
start
also
screen
vitro
may
way
ahead
cancer
therapi
color
blind
marksman
use
red
green
delin
target
would
clearli
present
difficulti
aim
genet
variat
target
molecul
present
far
complex
challeng
pharmacologist
mani
experiment
condit
use
hybridoma
cell
line
inbr
laboratori
anim
speci
goe
way
ensur
genet
background
cell
organ
similar
wherev
experi
perform
expect
ensur
genet
background
remain
reason
constant
cellular
physiolog
respons
standard
condit
also
remain
rel
constant
unfortun
alway
case
even
underli
genet
background
similar
happen
gene
express
differ
cell
medium
use
cell
line
taken
vari
time
passag
incub
condit
use
result
differ
rate
growth
mani
cell
biologist
familiar
fact
cell
line
becom
unrespons
due
form
gene
silenc
cultur
prolong
period
recent
discoveri
clearli
show
cell
respond
differ
ph
oxygen
concentr
alter
occur
instanc
inflamm
ischemia
consequ
effect
test
drug
chang
addit
cell
stimuli
often
group
togeth
scientif
investig
basi
ultim
result
gener
cell
product
similar
outcom
instanc
prostaglandin
pg
product
macrophag
use
decad
experiment
readout
respons
inflammatori
stimulu
keep
patholog
situat
gener
follow
stimul
macrophag
complex
calcium
ionophor
phagocytosi
occur
influenc
differ
signal
pathway
cell
differ
phenotyp
importantli
also
exert
effect
includ
suppress
phagocytosi
trigger
resolut
phase
acut
inflamm
subsid
thu
lipid
inhibit
product
via
neg
feedback
loop
induc
gener
proresolv
mediat
therebi
modul
subsequ
adapt
type
inflammatori
stimulu
time
inflammatori
phase
cell
collect
well
type
respons
measur
markedli
alter
effect
compound
test
see
also
section
time
age
resolut
diseas
use
defin
stimulu
elicit
particular
pharmacolog
phenotyp
respons
standard
cellular
biolog
test
system
would
seem
solut
mani
issu
outlin
across
varieti
laboratori
respons
pharmacolog
intervent
compar
much
easili
problem
natur
play
fair
diseas
syndrom
result
whole
rang
differ
trigger
agent
far
possibl
drug
screen
therefor
carri
milieu
reflect
target
diseas
environ
macrophag
remark
plastic
depend
stimulu
appli
express
macrophag
gene
highli
suscept
epigenet
modif
silenc
gene
activ
consequ
macrophag
express
wide
rang
phenotyp
classic
inflammatori
altern
activ
macrophag
research
consid
cell
continu
dynam
state
alter
phenotyp
accord
condit
extracellular
moreov
polar
macrophag
particular
phenotyp
tight
metabol
regul
chang
glucos
ph
nutrient
chang
genet
express
profil
appear
relat
rewir
citric
acid
kreb
cycl
inflammatori
stimuli
simpl
product
cycl
citrat
succin
fumar
exert
remark
chang
macrophag
dendrit
cell
also
shown
recent
rest
polar
state
primari
human
macrophag
macrophag
cell
line
differ
latter
polar
state
relev
modif
gene
express
consequ
differ
form
cell
term
cell
line
primari
cell
particularli
white
blood
cell
necessarili
produc
similar
respons
abl
gain
accur
assess
effect
pharmacolog
agent
type
cell
therefor
crucial
select
varieti
cell
phenotyp
differ
physiolog
relev
stimuli
evalu
gene
express
cell
signal
surfac
molecul
express
chang
well
determin
secret
product
varieti
drug
report
chang
phenotyp
macrophag
vitro
care
dissect
spectrum
respons
need
identifi
differ
pharmacolog
mechan
gene
regul
epigenet
mechan
histon
acetyl
methyl
dna
methyl
wide
report
mani
cell
mechan
report
play
import
role
etiolog
cancer
led
introduct
histon
deacetylas
hdac
inhibitor
vorinostat
romidepsin
belinostat
panobinostat
inhibitor
tumor
prolifer
sever
type
howev
drug
differ
hdac
type
differ
specif
function
pronounc
clinic
moreov
addit
histon
protein
subject
acetyl
might
also
affect
hdac
activ
interestingli
appear
concomit
inhibit
inflamm
inhibitor
transcript
factor
nuclear
factor
may
act
synergist
hdac
inhibitor
reduc
indic
potenti
benefit
combin
drug
therapi
often
epigenet
modif
seen
healthi
transform
cell
studi
experiment
hour
day
case
effect
view
rather
cell
signal
respons
inherit
chang
assess
chang
better
way
assess
epigenet
inherit
done
quit
effect
zebrafish
insect
gener
turnov
much
rapid
mani
drug
particularli
anticanc
agent
discuss
modifi
posttransl
chang
type
drug
includ
analges
abl
modifi
epigenet
marker
histon
acetyl
dna
thu
silenc
activ
gene
may
continu
subsequ
gener
respect
warn
note
rais
find
discuss
earlier
treatment
male
mice
standard
chemotherapeut
drug
result
transgener
instabl
variabl
natur
popul
often
driven
environment
infect
induc
posttransl
genet
modif
highli
probabl
drug
treatment
may
need
includ
among
modifi
sensit
induct
experiment
model
autoimmun
diseas
highli
suscept
genet
background
strain
anim
use
often
result
differ
phenotyp
respond
differ
drug
instanc
wide
use
experiment
model
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
commonli
induc
mice
immunolog
challeng
myelin
oligodendrocyt
glycoprotein
import
autoantigen
cn
administ
immunolog
adjuv
freund
complet
adjuv
fca
kill
mycobacterium
tuberculosi
paraffin
oil
without
pertussi
toxin
make
barrier
permeabl
anim
develop
progress
form
paralysi
varieti
activ
compound
market
drug
develop
basi
activ
model
howev
minor
multipl
sclerosi
patient
exhibit
chronic
progress
form
diseas
common
form
occur
patient
better
reproduc
sjl
mice
challeng
myelin
proteolipid
protein
fca
pertussi
toxin
rat
rat
spinal
cord
homogen
fca
recent
shown
even
assess
establish
market
drug
eae
model
show
similar
respons
alreadi
approv
howev
even
model
show
littl
respons
term
clinic
score
assess
concurr
use
clinic
relev
variabl
behavior
social
interact
uncov
unexpect
efficaci
author
report
sensit
mechan
pain
eae
also
vari
sjl
lesson
drawn
genet
phenotyp
varieti
experiment
model
taken
account
partial
use
rang
genet
sensit
strain
select
translat
relev
assess
method
gener
efficaci
profil
provid
precis
pictur
drug
efficaci
viral
suscept
immun
attack
epitop
drift
genet
spread
also
occur
develop
autoimmun
complic
interpret
drug
effect
consequ
immun
system
begin
recogn
antigen
molecul
beyond
specif
extern
chemic
determin
specif
immun
respons
initi
lead
autoimmun
tissu
damag
also
recruit
varieti
differ
humor
cytotox
immunoregulatori
mechan
later
stage
mani
chronic
autoimmun
diseas
therefor
difficult
determin
basic
underli
defect
genet
biomark
studi
may
highlight
common
factor
diseas
variant
protein
antibodi
rheumatoid
arthriti
help
stratifi
patient
emphas
need
rang
diseas
assess
evalu
effect
drug
therapi
epitop
drift
also
complic
use
experiment
model
autoimmun
one
us
mjp
well
rememb
perform
seri
studi
year
ago
tissu
injur
effect
lymph
node
lymphocyt
lewi
wistar
rat
reactiv
lymphocyt
gradual
lost
time
presum
due
epitop
drift
project
stop
observ
support
result
studi
author
adjuv
arthriti
induc
spragu
dawley
rat
two
differ
rat
two
sourc
vari
suscept
arthriti
well
immun
variou
proinflammatori
cytokin
endocrin
plasma
acth
corticosteron
respons
author
suggest
differ
type
genet
drift
two
coloni
probabl
respons
possibl
rais
previou
would
well
worthwhil
carri
compar
studi
differ
lab
rang
antigen
reactiv
lymphocyt
anim
initi
stimulu
use
induc
autoimmun
respons
one
would
guess
reactiv
would
differ
consider
indic
research
necessarili
assess
respons
balanc
diet
essenti
metabol
cardiovascular
health
variat
diet
also
mark
effect
auto
immun
moreov
clear
chang
function
cell
macrophag
dendrit
cell
close
relat
metabol
laboratori
anim
fed
standard
laboratori
diet
chang
immun
respons
gener
due
administ
immunolog
stimuli
necessarili
translat
clinic
situat
dietari
condit
vari
consider
although
diet
control
phase
clinic
trial
human
volunt
dietari
control
much
less
feasibl
later
stage
trial
intak
variou
type
fatti
acid
trace
element
fruit
rich
vitamin
affect
immun
respons
exampl
adequ
zinc
selenium
intak
necessari
effect
function
immun
among
effect
zinc
import
cofactor
signal
therebi
facilit
differenti
matur
lymphocyt
well
promot
phagocyt
nk
cell
often
use
adjuv
treatment
infect
recommend
infecti
diarrhea
children
develop
selenium
crucial
function
antioxid
glutathion
peroxidas
famili
enzym
endogen
selenoprotein
thioredoxin
reductas
defici
selenium
associ
neutrophil
lymphocyt
defect
probabl
due
inadequ
protect
membran
oxid
vitamin
e
also
exert
similar
protect
action
membran
find
provid
consider
stimulu
use
dietari
supplement
strengthen
immun
respons
also
increas
evid
probiot
lactobacillu
modifi
constitut
gut
microbiom
also
promot
innat
immun
way
also
indirectli
enhanc
adapt
even
laboratori
anim
though
dietari
chang
occur
unexpectedli
one
studi
one
us
mjp
involv
eicosanoid
metabolit
includ
determin
period
sever
year
platelet
inflammatori
exud
differ
experi
laboratori
rat
fed
essenti
fatti
acid
defici
diet
time
quantiti
eicosanoid
gener
enigmat
sourc
eventu
found
unannounc
chang
made
diet
manufactur
sourc
oil
use
ensur
essenti
fatti
acid
defici
meantim
well
establish
chang
type
dietari
fatti
acid
mark
effect
structur
type
eicosanoid
gener
exampl
increas
dietari
intak
fatti
acid
occur
high
quantiti
fish
reduc
amount
convers
fatti
acid
arachidon
acid
metabolit
lead
synthesi
metabolit
either
differ
limit
biolog
activ
well
exert
inhibitori
effect
pe
se
inflammatori
mediat
moreov
fatti
acid
modifi
composit
gut
microbiom
promot
bacteria
less
proinflammatori
term
auto
immun
gut
colon
commens
segment
filament
bacteria
sfb
play
crucial
role
sfb
promot
mucos
iga
product
format
effector
cell
gut
peyer
patch
result
exacerb
inflamm
murin
model
coliti
autoimmun
encephalomyel
arthriti
protect
effect
gut
microbiom
drug
metabol
efficaci
consid
section
surprisingli
although
presenc
absenc
food
affect
oral
drug
absorpt
studi
carri
investig
effect
differ
dietari
constitu
respons
drug
dietari
supplement
sodium
selenit
pregnanc
rat
report
increas
surviv
embryotox
induc
concomitantli
administ
sodium
salicyl
though
mechan
effect
reactiv
oxygen
speci
seem
like
nude
mice
experiment
induc
pulmonari
tumor
place
high
fat
wtwt
linol
acid
diet
nsaid
indomethacin
found
significantli
reduc
tumor
howev
longitudin
clinic
studi
patient
colorect
cancer
posit
interact
diet
aspirin
administr
cancer
incid
could
thu
chang
dietari
constitu
markedli
influenc
immun
respons
much
remain
done
assess
whether
variat
diet
modifi
drug
efficaci
perhap
step
could
view
attempt
modifi
fuel
use
biolog
traffic
environment
friendli
form
flexibl
mobil
molecul
cell
certainli
explain
type
pharmacolog
plastic
chang
extern
environ
addit
modifi
epigenet
profil
nutrit
condit
gut
microbiom
also
modifi
target
respons
drug
modern
propens
travel
instanc
carri
addit
constraint
us
awar
physic
challeng
intercontinent
air
travel
jetlag
sleepless
lack
concentr
difficulti
adjust
season
daylight
alter
reason
whole
organ
includ
individu
cell
regul
bodi
clock
autoregulatori
product
cellular
clock
gene
regul
transcript
factor
control
daili
circadian
season
jetlag
result
predominantli
modif
suprachiasmat
nucleu
master
bodi
clock
govern
subsequ
chang
peripheri
includ
alter
secret
melatonin
pineal
gland
govern
sleepwak
light
thu
wide
view
time
giver
german
zeitgeb
sleep
behavior
regul
releas
pineal
hormon
melatonin
cours
diseas
also
modul
exampl
common
symptom
rheumat
diseas
morn
stiff
result
disturb
patient
diurnal
modul
axi
endogen
cortisol
level
seen
also
corticosteron
experiment
arthriti
cortisol
level
inappropri
low
patient
earli
morn
mirror
chang
peripher
blood
mononuclear
cell
count
proinflammatori
cytokin
opposit
circadian
restor
normal
circadian
rhythm
may
well
reason
year
past
patient
rheumat
diseas
improv
consider
sent
sanatoria
sunni
countri
help
explain
regen
effect
sleep
variou
disord
express
receptor
glucocorticoid
peripher
cell
tissu
also
vari
circadian
rhythm
sensit
tissu
therapeut
corticosteroid
also
chang
sinc
receptor
sensit
low
morn
high
even
propos
may
basi
adjust
time
corticosteroid
therapi
reduc
side
similar
circadian
rhythm
observ
efficaci
pharmacokinet
nsaid
probabl
chang
circul
moreov
blood
pressur
also
control
circadian
rhythm
propos
antihypertens
therapi
given
bedtim
achiev
optim
pain
also
underli
circadian
rhythm
importantli
melatonin
thought
exert
analges
similarli
respiratori
disord
allerg
respons
gastrointestin
disturb
subject
chang
light
grow
evid
patient
sever
sepsi
kept
intens
care
unit
day
circadian
rhythm
disturb
modif
light
dark
cycl
intensifi
contrast
minim
disrupt
treat
melatonin
exert
benefici
effect
outcom
least
disord
worth
point
cyclic
circul
concentr
melatonin
potent
antioxid
agent
may
exert
direct
effect
variabl
markedli
affect
sensit
respons
molecular
target
alter
respons
drug
action
cyclic
chang
may
diurnal
occur
period
season
circannu
chang
aris
result
shorten
lengthen
daylight
time
great
signific
laboratori
anim
kept
control
condit
highli
like
pharmacolog
respons
mani
drug
human
howev
depend
circadian
circannu
rhythm
shown
recent
gene
associ
immun
system
white
blood
cell
adipos
tissu
show
mark
circannu
europ
peak
express
gene
circadian
transcript
factor
aryl
hydrocarbon
receptor
nuclear
nadir
inflammatori
gene
occur
juli
revers
decemb
opposit
pattern
seen
oceania
least
human
introduct
healthi
diet
regular
sleep
exercis
go
long
way
toward
synchron
mani
biorhythm
stabil
drug
target
interestingli
modif
lifestyl
clear
effect
chromatin
modif
reflect
extent
biolog
find
provid
evid
possibl
modifi
drug
diet
exercis
epigenet
process
associ
deterior
advers
mutat
underli
biorhythm
alter
properti
drug
target
physiolog
patholog
process
also
chang
time
biomolecul
particular
protein
dynam
interact
alter
locat
undergo
movement
gener
slow
time
becom
less
flexibl
dysfunct
tau
protein
prion
neurodegen
disord
lipoprotein
atherosclerosi
predominantli
due
increas
oxid
time
progress
tachyphylaxi
loss
drug
efficaci
occur
probabl
protein
receptor
desensit
cellular
senesc
even
target
hit
effect
longer
use
traffic
metaphor
traffic
start
move
slowli
break
caus
increas
congest
thu
obviou
effect
time
seen
effect
age
major
issu
societi
age
popul
elderli
peopl
far
suscept
diseas
partial
slow
deterior
normal
physiolog
especi
renal
function
also
dysfunct
defens
repair
mechan
gradual
decreas
barrier
function
mucosa
elderli
develop
innat
immun
senesc
affect
cell
innat
immun
polypharmaci
patient
common
heterogen
studi
drug
use
group
patient
hinder
develop
approach
toward
risk
analysi
prescrib
data
obtain
adult
period
year
taysid
scotland
patient
receiv
dispens
drug
per
day
experienc
seriou
interact
compar
two
four
drug
often
addit
drug
prescrib
combat
previous
prescrib
drug
situat
akin
exampl
describ
take
shotgun
hit
small
target
result
unnecessari
collater
damag
good
mani
elderli
patient
regular
reassess
number
dose
drug
administ
highli
advis
author
person
awar
sever
elderli
patient
whose
condit
improv
consider
drug
treatment
markedli
reduc
less
sometim
fact
recent
report
describ
improv
glycem
control
diabet
patient
follow
reduct
complex
medic
nevertheless
author
well
awar
elderli
patient
multipl
morbid
appropri
polypharmaci
may
need
treat
patient
problem
coupl
guidelin
deal
situat
comorbid
case
patient
suffer
concurr
sever
diseas
inappropri
simpli
combin
drug
recommend
respect
guidelin
cover
individu
diseas
market
drug
introduc
specif
mechan
action
often
involv
singl
major
target
develop
drug
pathophysiolog
role
rel
novel
target
mechan
may
inadequ
understood
later
often
result
clinic
use
drug
patholog
role
target
mechan
diseas
process
becom
clearer
clarif
also
includ
time
phase
diseas
process
target
mechan
intim
involv
therefor
suscept
pharmacolog
intervent
unfortun
improv
understand
optim
time
drug
administr
alway
lead
modif
diseas
therapi
sinc
establish
drug
use
tend
modifi
result
limit
result
optim
efficaci
base
improv
understand
pharmacolog
two
exampl
import
time
drug
efficaci
cite
acetylsalicyl
acid
aspirin
use
analges
antipyret
therapi
nearli
year
use
antiplatelet
potenti
anticanc
agent
estim
ton
acetylsalicyl
acid
synthes
annual
though
mani
case
togeth
nonsteroid
drug
nsaid
clearli
overus
particularli
case
elderli
mani
thousand
death
due
gastrointestin
bleed
patient
presum
prescrib
physician
unawar
fact
nsaid
gener
provid
symptomat
relief
pain
inflamm
littl
effect
time
cours
acut
inflamm
certainli
true
common
cold
viral
infect
inflammatori
symptom
case
use
nsaid
advis
reduc
initi
inflammatori
symptom
avoid
potenti
inhibit
activ
gener
endogen
proresolv
lipid
drug
facilit
resolut
inflamm
macrolid
antibiot
azithromycin
promot
gener
proresolv
macrophag
phenotyp
macrolid
known
particularli
effect
treatment
respiratori
infect
commun
acquir
pneumonia
acut
exacerb
chronic
obstruct
pulmonari
diseas
well
rare
inflammatori
lung
disord
diffus
panbronchiol
macrolid
antibiot
accumul
leukocyt
caus
initi
stimul
neutrophil
function
thu
antibacteri
activ
subsequ
promot
gener
macrophag
phenotyp
resolut
consequ
antibacteri
use
requir
day
administr
extend
use
limit
number
inflammatori
condit
macrolid
without
antibacteri
activ
also
develop
immunomodulatori
moreov
capac
azithromycin
promot
macrophag
phenotyp
also
shown
potenti
therapeut
benefit
treatment
cerebr
ischem
recognit
potenti
mechan
target
drug
treatment
particular
diseas
therefor
mean
administ
time
patient
diseas
time
stage
diseas
treat
also
crucial
success
therapi
durat
drug
action
factor
assess
interact
target
avoid
pass
consider
articl
intramolecular
dynam
drug
target
molecul
worth
mention
one
aspect
bind
affect
durat
drug
action
resid
time
model
gain
increas
accept
last
decad
describ
interact
drug
molecular
affin
drug
receptor
domin
theoret
consider
past
new
theori
assess
interact
term
time
drug
engag
receptor
slower
drug
dissoci
target
receptor
longer
durat
action
potenti
would
mean
retent
drug
site
action
prolong
effect
azithromycin
could
inde
case
accumul
rapidli
leukocyt
slowli
releas
cell
allow
time
exert
proresolv
immunomodulatori
pattern
azithromycin
also
fetal
tracheal
epitheli
cell
would
definit
great
particular
chronic
diseas
therapi
compar
drug
moder
intrins
activ
receptor
prolong
durat
action
efficaci
potent
drug
high
intrins
activ
could
surpris
past
preclin
studi
drug
candid
perform
exclus
male
anim
avoid
inconveni
alter
sensit
result
endogen
hormon
chang
long
clear
femal
respons
drug
often
vari
male
differ
start
sex
differ
diseas
suscept
possibl
part
sex
chromosom
linkag
also
due
hormon
metabol
distinct
physic
constitut
lifestyl
obviou
autoimmun
diseas
often
preval
femal
male
system
lupu
erythematosu
diseas
occur
mainli
femal
system
sclerosi
fourfold
rheumatoid
arthriti
threefold
multipl
sclerosi
twofold
frequent
femal
femal
also
typic
develop
higher
antibodi
respons
experi
advers
reaction
vaccin
similar
find
recent
made
collagen
type
ii
arthriti
da
rat
femal
ratio
cell
treg
cell
rais
product
immunoglobulin
increas
femal
comparison
contrast
sepsi
less
pronounc
physiolog
resolut
acut
vascular
inflamm
human
appear
effect
women
suggest
breakdown
effect
resolut
mechan
may
account
least
partial
sever
sequella
chronic
inflammatori
disord
women
interestingli
appear
effect
sex
hormon
neuroimmun
system
may
also
account
higher
incid
chronic
pain
increas
sensit
pain
schizophrenia
though
frequent
young
male
femal
wherea
ratio
revers
adulthood
probabl
protect
effect
sex
differ
also
repeatedli
report
incid
drug
efficaci
depress
men
women
wherea
sex
differ
also
found
anim
model
depress
consequ
relev
subsequ
clinic
develop
especi
term
autoimmun
neurolog
diseas
use
femal
anim
least
anim
sex
earli
compound
fact
us
nation
institut
health
recommend
sex
anim
cell
balanc
preclin
research
us
feder
drug
administr
encourag
pharmaceut
medic
devic
compani
provid
data
clinic
trial
deriv
men
howev
mean
number
anim
human
subject
includ
trial
increas
statist
reason
fact
need
taken
account
local
regulatori
author
pharmacolog
action
drug
also
subject
sex
differ
particularli
relat
cardiovascular
effect
recent
variabl
partial
genet
base
indic
instanc
regard
sensit
sex
differ
receptor
sensit
exist
distinct
male
femal
especi
pronounc
pharmacokinet
process
sinc
express
mani
drug
metabol
enzym
occurr
advers
drug
effect
subject
modif
femal
sex
author
review
emphas
crucial
design
clinic
trial
abl
distinguish
respons
base
sex
clearli
assess
confound
effect
sex
hormon
sourc
plastic
respons
drug
major
reason
drug
miss
target
kinet
fate
within
bodi
instanc
sex
hormon
affect
ph
motil
gastric
intestin
tract
also
express
oxid
metabol
enzym
membran
transport
broadli
genet
polymorph
mani
drug
metabol
enzym
complic
consider
determin
suitabl
dose
clinic
studi
polymorph
oxid
metabol
cytochrom
cyp
well
document
basi
clear
guidelin
assess
potenti
interact
term
metabol
interfer
concomit
drug
consid
earlier
metabol
interact
becom
even
import
elderli
polypharmaci
common
rate
metabol
decreas
make
interact
much
exercis
sport
one
hand
factor
smoke
hand
profound
effect
express
metabol
enzym
effect
includ
discret
modif
methyl
key
metabol
regulatori
enzym
adenosin
protein
kinas
blood
skelet
muscl
consequ
lifestyl
chang
may
affect
suscept
diseas
discuss
relat
chronobiolog
also
metabol
drug
gut
microbiom
exert
profound
effect
drug
metabol
thu
metabol
gut
microbiota
urem
solut
bile
acid
steroid
hormon
lead
modif
phase
oxid
reaction
well
phase
ii
drug
conjug
enzym
sulfotransferas
affect
metabol
number
convers
bacteri
enzym
directli
metabol
drug
therebi
affect
efficaci
bacteri
azoreductas
colon
instanc
degrad
sulfasalazin
drug
use
inflammatori
bowel
diseas
crohn
ulcer
coliti
activ
metabolit
acid
sulfapyridin
nevertheless
rat
acid
tnb
coliti
model
sulfasalazin
abl
restor
gut
dysbiosi
reflect
increas
count
fatti
acid
scfa
lactic
bacteria
well
decreas
count
proteobacteria
therebi
amelior
enhanc
scfa
product
gut
bacteria
also
thought
one
mechan
type
drug
metformin
modifi
glucos
metabol
cardiovascular
thu
chang
gut
microbiom
caus
diet
lifestyl
differ
potenti
alter
metabol
therebi
efficaci
drug
even
similar
strain
rodent
sinc
discuss
previous
anim
differ
supplier
differ
respons
inde
extens
sequenc
analysi
gut
microbiom
three
differ
mous
strain
two
supplier
reveal
consider
differ
bacteri
composit
strain
differ
polymorph
drug
transport
protein
subtl
sourc
concern
sinc
differ
affect
metabol
behavior
drug
also
specif
distribut
organ
tissu
cell
one
hand
efflux
transport
drug
tumor
bacteria
major
reason
drug
necessit
continu
develop
new
approach
cancer
infect
prefer
use
multitarget
approach
minim
potenti
hand
differ
drug
transport
known
affect
hepat
transport
kidney
excret
drug
also
worthwhil
note
transport
protein
also
affect
drug
transport
tissu
organ
instanc
organ
polypeptid
oatp
regul
intestin
absorpt
macrolid
oatp
highli
express
brain
appear
regul
drug
transport
across
polymorph
oatp
wide
spectrum
pharmacolog
substrat
crucial
import
effect
could
potenti
affect
cn
bioavail
screen
patient
oatp
polymorph
could
potenti
optim
therapi
relev
drug
pharmacovigil
thu
requir
evalu
clinic
report
accident
unexpect
metabol
interact
perform
proactiv
recommend
protect
screen
measur
taken
base
new
data
literatur
seek
modifi
exist
prescript
behavior
elderli
varieti
technolog
approach
taken
prolong
durat
drug
action
particularli
formul
thu
combat
variat
drug
metabol
includ
delay
absorpt
use
excipi
allow
slow
releas
activ
ingredi
formul
drug
hijack
transport
respect
interest
new
approach
recent
appear
incorpor
deuterium
heavi
hydrogen
atom
place
hydrogen
drug
molecul
creat
stronger
bond
carbon
wide
use
synthes
refer
compound
drug
analysi
mass
spectrometri
drug
tetrabenazin
also
long
use
treatment
hyperkinesia
well
huntingdon
diseas
introduc
deuterium
tetrabenazin
molecul
shown
metabol
molecul
site
slow
peak
plasma
concentr
potenti
view
immens
variabl
plastic
mammalian
organ
respons
pharmacolog
agent
entir
surpris
drug
alway
provid
benefit
expect
fact
admit
even
new
drug
market
know
rel
littl
efficaci
larg
popul
subsequ
mani
drug
prescrib
often
unsuit
condit
patient
will
take
medicin
condit
may
requir
treatment
asid
nonadher
also
big
problem
apart
highli
specif
drug
monoclon
antibodi
may
worth
reconsid
ration
approach
drug
therapi
name
use
singl
specif
drug
hit
singl
target
like
ehrlich
magic
bullet
rather
consid
multipl
factor
make
target
difficult
hit
tri
use
progress
multifactori
multitarget
approach
enough
exampl
techniqu
natur
world
lioness
hunt
fast
move
gyrat
antelop
group
initi
reduc
space
within
antelop
move
one
attack
may
abl
injur
slow
prey
other
come
kill
approach
use
militari
action
slow
damag
superior
oppon
therebi
becom
easier
destroy
use
metaphor
start
introduct
sometim
crazi
movement
car
major
road
intersect
best
control
forc
car
specif
lane
introduc
traffic
light
potenti
traffic
jam
markedli
reduc
pharmacolog
term
achiev
use
differ
drug
compar
concept
propos
relat
drug
dose
use
treatment
author
instanc
suggest
combin
low
dose
analges
drug
act
differ
stage
gener
action
releas
substrat
phospholipas
metabol
arachidon
acid
microsom
pge
synthas
final
action
differ
receptor
could
use
way
advers
gastric
cardiovascular
effect
aris
pronounc
inhibit
nsaid
could
markedli
reduc
altern
immun
reaction
neurolog
defici
could
potenti
regul
light
melatonin
make
final
target
access
treatment
growth
dysregul
cancer
cell
could
slow
time
avail
target
specif
mechan
way
serial
use
two
three
pharmacolog
agent
prefer
long
resid
time
would
probabl
greater
efficaci
singl
potent
agent
prove
effect
limit
number
patient
inher
instabl
target
mechan
approach
alreadi
taken
good
effect
treatment
hypertens
diuret
instanc
combin
sartan
andor
calcium
antagonist
consist
decreas
blood
emphas
four
alreadi
exist
approach
figur
taken
either
singli
combin
tri
minim
effect
pharmacolog
plastic
aim
drug
singl
multipl
target
aim
precis
provid
greater
chanc
avoid
effect
despit
long
histori
drug
target
year
improv
still
room
enhanc
chemic
specif
drug
design
stage
intriguingli
recent
detail
dock
studi
million
compound
reveal
possibl
bia
effect
compound
act
singl
receptor
toward
one
downstream
signal
process
dock
led
identif
compound
preferenti
activ
signal
g
protein
gi
clear
analges
activ
avoid
signal
pathway
associ
respiratori
depress
constip
view
much
increas
understand
signal
pathway
might
promis
approach
screen
condit
addit
reflect
close
possibl
occur
immedi
environ
put
diseas
target
recent
review
drawn
gener
set
genom
context
cellular
heterogen
incub
condit
relev
suitabl
vitro
screen
cell
system
even
repurpos
known
drug
new
indic
specif
context
set
guidelin
propos
facilit
vitro
test
select
kinas
varieti
order
defin
potenti
therapeut
benefici
pharmacolog
stratif
anim
clinic
system
base
biomark
genet
cluster
well
age
sex
diseas
stage
even
diet
consider
circadian
circannu
rhythm
also
improv
specif
gain
hold
less
easili
control
variabl
essenti
make
effect
use
refer
compound
involv
check
whether
respons
remain
condit
whether
pharmacolog
respons
test
situat
expect
sinc
refer
compound
may
also
effect
biomark
mechan
action
includ
sever
mechan
current
usual
involv
treat
diseas
multipl
drug
alreadi
seen
elderli
caus
problem
prefer
individu
drug
develop
multipl
relev
action
recent
studi
suggest
singl
small
molecul
compound
may
develop
hit
sever
target
simultan
thu
glitazon
compound
describ
recent
metabol
disord
partial
agonist
potent
antagonist
nanomolar
valu
moder
inhibitor
micromolar
valu
activ
compound
macrophag
vitro
acut
inflamm
whether
activ
requir
mechan
action
attribut
one
two
remain
establish
approach
includ
network
target
optogenet
neuron
circuit
modul
mark
specif
gene
rhodopsin
respond
phenotyp
assay
use
function
readout
oppos
singl
assay
consider
interest
arisen
use
phenotyp
assay
primari
cellular
stem
cell
system
vitro
anim
model
instanc
report
stimul
gener
neurogenesi
human
neural
stem
cell
vitro
abl
exert
multidomain
effect
cognit
depress
suggest
phenotyp
multitarget
may
also
viabl
cn
challeng
identifi
possibl
revers
pharmacolog
extrapol
backward
clinic
condit
phenotyp
set
symptom
use
potenti
function
target
initi
screen
subsequ
activ
hit
lead
compound
identifi
target
deconvolut
carri
investig
potenti
mechan
action
recent
propos
made
establish
chain
translat
start
identif
molecular
characterist
signatur
gene
express
succeed
cellular
model
aim
reconstruct
cellular
phenotyp
similar
possibl
diseas
condit
subsequ
use
relev
anim
model
diseas
altern
wide
rang
assay
readout
use
system
biolog
approach
taken
assess
data
pattern
approach
also
taken
laboratori
use
differ
test
model
rang
function
molecular
biochem
imag
method
variou
stage
compound
test
reflect
clinic
target
consist
complex
interact
mechan
pain
comput
function
approach
help
improv
accuraci
clarifi
specif
target
aim
defin
pain
type
also
offer
insight
target
mechan
pharmacolog
modif
either
individu
drug
combin
therapeut
target
move
hitkil
aim
sequenti
one
target
upstream
one
target
downstream
use
singl
drug
multipl
action
combin
drug
vari
action
illustr
combin
singl
dosag
form
antibiot
sulfamethoxazol
inhibitor
dihydroptero
synthetas
trimethoprim
inhibitor
dihydrofol
reductas
togeth
act
synergist
inhibit
bacteri
synthesi
tetrahydrofol
acid
exampl
approach
sequenti
combin
drug
act
differ
stage
cell
signal
pathway
sever
growth
factor
act
kinas
b
pathway
crucial
cell
prolifer
angiogenesi
downstream
effector
pathway
regulatori
protein
mammalian
target
rapamycin
mtor
addit
anticanc
drug
docetaxol
adenocarcinoma
cell
vitro
hour
follow
mtor
inhibitor
temsirolimu
highli
synergist
suppress
phosphoryl
mtor
well
suppress
prolifer
lung
cancer
cell
author
propos
sequenti
combin
may
effect
overcom
resist
tumor
mtor
inhibitor
use
similar
rational
phase
studi
carri
tubulin
polymer
inhibitor
administ
togeth
mtor
inhibitor
everolimu
patient
metastat
renal
cell
carcinoma
refractori
tyrosin
kinas
primari
endpoint
reach
analysi
biomark
suggest
studi
warrant
chronic
diseas
inhibit
epigenet
chang
result
slow
chromatin
age
process
may
soon
possibl
make
patient
amen
type
therapi
concurr
dietari
psycholog
train
procedur
optim
drug
therapi
take
account
standard
possibl
chang
respons
time
age
wide
varieti
differ
pharmacolog
physic
nutrit
procedur
use
hospit
set
treat
ill
patient
howev
therapeut
program
synchron
variou
factor
discuss
rare
consider
potenti
appear
exist
modifi
gut
microbiota
improv
drug
efficaci
discuss
previous
relat
drug
metabol
thu
modul
gut
bacteri
popul
increas
evid
efficaci
current
anticanc
chemotherapeut
enhanc
toxic
perhap
simpl
measur
regular
use
probiot
obvious
treatment
human
diseas
drug
therapi
usual
one
measur
taken
improv
health
patient
optim
condit
implement
support
measur
often
assess
certainli
preclin
investig
instanc
efficaci
appetit
suppress
diethylpropion
use
clinic
caus
weight
loss
greater
given
rat
night
activ
greatest
anim
also
place
high
fat
dietari
mani
chronic
diseas
muscl
loss
occur
gener
metabol
defici
aris
chronic
obstruct
pulmonari
diseas
instanc
increas
evid
combin
nutrit
exercis
intervent
effect
use
combin
drug
contrast
treatment
cancer
calor
restrict
ketogen
diet
found
enhanc
drug
efficaci
reduc
measur
taken
synchron
treatment
studi
made
set
time
season
allow
fact
durat
action
drug
long
synchron
drug
therapi
factor
undoubtedli
becom
possibl
near
futur
combin
use
drug
diagnost
devic
big
data
becom
increasingli
case
even
establish
drug
crucial
vigil
awar
new
find
impact
way
drug
prescrib
use
mjp
consult
leo
pharma
xellia
pharmaceut
previous
employe
glaxosmithklin
gg
member
imi
innov
medicin
initi
eu
europain
collabor
follow
industri
member
repres
astra
zeneca
boehring
ingelheim
eli
lilli
estev
gruenenth
pfizer
ucb
pharma
sanofi
aventi
gg
receiv
honoraria
speaker
gruenenth
mundipharma
pfizer
consult
abbvi
receiv
research
fund
form
grant
mundipharma
author
involv
draft
manuscript
revis
critic
import
intellectu
content
given
final
approv
version
publish
account
aspect
work
data
avail
statement
data
use
obtain
secondari
sourc
endnot
rrid
europ
pubm
central
rrid
googl
rrid
repres
inform
otherwis
known
person
one
author
cite
possibl
link
data
repositori
thu
relev
